Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020

Nancy Herrera-Leaño, Julián E. Barahona-Correa, Oscar Muñoz-Velandia, Daniel G. Fernández-ávila, Ángel A. García

Producción: Contribución a una revistaArtículorevisión exhaustiva

Resumen

Introduction: Real-life adherence to the management of heart failure is suboptimal. Adherence to the recommendations for the use of sacubitril/valsartan in Colombia is unknown. Objective: To assess the frequency of use, geographic distribution, and demo-graphic characteristics of patients who were prescribed sacubitril/valsartan in 2019-2020, using data from the “Sistema Integrado de Información de Protección Social” (SISPRO). Materials and method: This is a descriptive cross-sectional study. Information was extracted on the prescription distribution by department, gender, five-year age groups and the ICD-10 codes with which the medication was prescribed. Results: Between 2019 and 2020, 23,026 patients in Colombia were prescribed sacubitril/valsartan; 63.86% of the patients were men. Ninety-two percent of the prescriptions were for patients over the age of 50. The regions of the country with the highest prescription frequency were Bogotá, Sucre and Santander. Conclusions: Taking into account the estima-ted prevalence of heart failure (2-3%), the frequency with which sacubitril/valsartan is prescribed in Colombia is lower than expec-ted. The rural regions of the country have the lowest use, which suggests access barriers that should be explored.

Título traducido de la contribuciónFrequency and geographical distribution of the use of sacubitril/valsartan in Colombia between 2019 and 2020
Idioma originalEspañol
Páginas (desde-hasta)12-18
Número de páginas7
PublicaciónRevista Colombiana de Cardiologia
Volumen31
N.º1
DOI
EstadoPublicada - 01 ene. 2024

Palabras clave

  • Colombia
  • Heart failure
  • Sacubitril/valsartan

Huella

Profundice en los temas de investigación de 'Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020'. En conjunto forman una huella única.

Citar esto